Although comparison with anti‐CD19 CAR‐T infusion is limited by various CAR constructs and signaling, these results at least support that dual‐targeting CAR‐T‐associated toxicity is tolerable in B‐ALL. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.